Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P.
The effects of the challenge dose and major histocompatibility complex (MHC) class IB alleles were analyzed in 112 Mauritian cynomolgus monkeys vaccinated (n = 67) or not vaccinated (n = 45) with Tat and challenged with simian/human immunodeficiency virus (SHIV) 89.6P(cy243.) In the controls, the challenge dose (10 to 20 50% monkey infectious doses [MID(50)]) or MHC did not affect susceptibility to infection, peak viral load, or acute CD4 T-cell loss, whereas in the chronic phase of infection, the H1 haplotype correlated with a high viral load (P = 0.0280) and CD4 loss (P = 0.0343). Vaccination reduced the rate of infection acquisition at 10 MID(50) (P < 0.0001), and contained acute CD4 loss at 15 MID(50) (P = 0.0099). Haplotypes H2 and H6 were correlated with increased susceptibility (P = 0.0199) and resistance (P = 0.0087) to infection, respectively. Vaccination also contained CD4 depletion (P = 0.0391) during chronic infection, independently of the challenge dose or haplotype.
Cafaro
Aurelio
A
National AIDS Center, Istituto Superiore Sanità, Viale Regina Elena, 299, 00161 Rome, Italy.
Bellino
Stefania
S
Titti
Fausto
F
Maggiorella
Maria Teresa
MT
Sernicola
Leonardo
L
Wiseman
Roger W
RW
Venzon
David
D
Karl
Julie A
JA
O'Connor
David
D
Monini
Paolo
P
Robert-Guroff
Marjorie
M
Ensoli
Barbara
B
D016915:AIDS Vaccines / Q000008:administration & dosage / Q000276:immunology; D000818:Animals; D004195:Disease Models, Animal; D004306:Dose-Response Relationship, Immunologic; D006678:HIV / Q000276:immunology*; D015658:HIV Infections / Q000235:genetics* / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D006239:Haplotypes; D015395:Histocompatibility Antigens Class I / Q000235:genetics* / Q000276:immunology; D006801:Humans; D008252:Macaca fascicularis; D016097:Simian Acquired Immunodeficiency Syndrome / Q000235:genetics* / Q000276:immunology* / Q000517:prevention & control / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000276:immunology*; D014611:Vaccination; D019562:Viral Load; D054322:tat Gene Products, Human Immunodeficiency Virus / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*
D016915:AIDS Vaccines; D015395:Histocompatibility Antigens Class I; D054322:tat Gene Products, Human Immunodeficiency Virus